atamestane
Small moleculeexperimental
Atamestane, also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer. It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Oct 1, 2000 (NCT00010322)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Cytochrome P450 19A1INHIBITOR
CYP19A1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1=CC(=O)C=C2CC[C@@H]3[C@H](CC[C@]4(C)C(=O)CC[C@@H]34)[C@@]12C- Mol. weight
- 298.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAtamestane ↗
- ChEMBLCHEMBL2105987 ↗
Also known as
- 1-methyl-1,4-androstadiene-3,17-dione
- androsta-1,4-diene-3,17-dione, 1-methyl-
- atamestane
- atamestane
- atamestane
- atamestane
- atamestane
- sh489
- sh 489
- sh-489
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00267553 | Phase 3 | Nov 1, 2005 | Intarcia Therapeutics |
| NCT00097344 | Phase 3 | Dec 1, 2004 | Intarcia Therapeutics, Mayo Clinic |
| NCT00044291 | Phase 3 | Jun 1, 2002 | Intarcia Therapeutics, University of Toronto |
| NCT00010322 | Phase 3 | Oct 1, 2000 | Intarcia Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intarcia Therapeutics | For profit | 4 | 4 | 1 | 2000 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2002 |
3 organizations
Page 1 / 1